- Home
- SMTI vs CLLS Comparison
SMTI vs CLLS Comparison
Compare SMTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTI
- CLLS
- Stock Information
- Founded
- SMTI 1982
- CLLS 1999
- Country
- SMTI United States
- CLLS France
- Employees
- SMTI N/A
- CLLS N/A
- Industry
- SMTI Medical/Dental Instruments
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- SMTI Health Care
- CLLS Health Care
- Exchange
- SMTI Nasdaq
- CLLS Nasdaq
- Market Cap
- SMTI 252.1M
- CLLS 143.4M
- IPO Year
- SMTI N/A
- CLLS 2007
- Fundamental
- Price
- SMTI $29.84
- CLLS $1.59
- Analyst Decision
- SMTI Strong Buy
- CLLS Buy
- Analyst Count
- SMTI 2
- CLLS 1
- Target Price
- SMTI $49.50
- CLLS $4.00
- AVG Volume (30 Days)
- SMTI 51.8K
- CLLS 48.9K
- Earning Date
- SMTI 08-11-2025
- CLLS 08-05-2025
- Dividend Yield
- SMTI N/A
- CLLS N/A
- EPS Growth
- SMTI N/A
- CLLS N/A
- EPS
- SMTI N/A
- CLLS N/A
- Revenue
- SMTI $91,569,883.00
- CLLS $54,747,000.00
- Revenue This Year
- SMTI $23.53
- CLLS $48.52
- Revenue Next Year
- SMTI $5.93
- CLLS $5.17
- P/E Ratio
- SMTI N/A
- CLLS N/A
- Revenue Growth
- SMTI 34.65
- CLLS 351.26
- 52 Week Low
- SMTI $25.86
- CLLS $1.10
- 52 Week High
- SMTI $39.08
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- SMTI 53.37
- CLLS 56.98
- Support Level
- SMTI $29.80
- CLLS $1.56
- Resistance Level
- SMTI $30.94
- CLLS $1.49
- Average True Range (ATR)
- SMTI 1.07
- CLLS 0.09
- MACD
- SMTI 0.29
- CLLS 0.01
- Stochastic Oscillator
- SMTI 73.17
- CLLS 80.00
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.